Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices

被引:55
作者
Barbour, April [2 ]
Scaglione, Francesco
Derendorf, Hartmut [1 ]
机构
[1] Univ Florida, Dept Pharmaceut, Coll Pharm, Gainesville, FL 32610 USA
[2] GlaxoSmithKline, King Of Prussia, PA USA
关键词
Anti-infectives; Tissue distribution; Pharmacokinetics/pharmacodynamics; EXPOSURE-RESPONSE ANALYSES; IN-VIVO PHARMACODYNAMICS; STAPHYLOCOCCUS-AUREUS; PROTEIN-BINDING; STREPTOCOCCUS-PNEUMONIAE; BACTERICIDAL ACTIVITY; HEALTHY-VOLUNTEERS; SOFT-TISSUES; CLINICAL PHARMACOKINETICS; AZITHROMYCIN CP-62,993;
D O I
10.1016/j.ijantimicag.2010.01.023
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The pharmacokinetic/pharmacodynamic (PK/PD) indices useful for predicting antimicrobial clinical efficacy are well established. The most common indices include the time free drug concentration in plasma is above the minimum inhibitory concentration (MIC) (fT>(MIC)) expressed as a percent of the dosing interval, the ratio of maximum concentration to MIC (C-max/MIC), and the ratio of the area under the 24-h concentration-time curve to MIC (AUC(0-24)/MIC). A single PK/PD index may correlate well with an entire antimicrobial class. For example, the beta-lactams correlate well with the fT>(MIC). However, other classes may be more complex and a single index cannot be generalised to the class, e. g. the macrolides. The rationale behind which PK/PD index best correlates with efficacy depends on several factors, including the mechanism of action, the microbial kill kinetics, the degree of protein binding and the degree of tissue distribution. Studies have traditionally emphasised the first two factors, whilst the significance of protein binding and tissue distribution is increasingly appreciated. In fact, the latter two factors may partially elucidate why the magnitude of reported target indices are not always as expected. For example, tigecycline and telithromycin are clinically efficacious with average serum concentrations below their MICs over a 24-h period. Therefore, to understand more fully the PK/PD relationship of antibiotics and to better predict the clinical efficacy of antibiotic dosing regimens, assessment of free drug concentrations at the site of action is warranted. (C) 2010 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:431 / 438
页数:8
相关论文
共 115 条
[21]   Comparison of β-lactam regimens for the treatment of Gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics [J].
Burgess, DS ;
Frei, CR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (05) :893-898
[22]   POSTANTIBIOTIC EFFECT OF IMIPENEM ON PSEUDOMONAS-AERUGINOSA [J].
BUSTAMANTE, CI ;
DRUSANO, GL ;
TATEM, BA ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (05) :678-682
[23]   In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates [J].
Cercenado, E ;
García-Garrote, F ;
Bouza, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (01) :77-81
[24]   Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline [J].
Conte, JE ;
Golden, JA ;
Kelly, MG ;
Zurlinden, E .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (06) :523-529
[25]   Extended-interval aminoglycoside administration for children: A meta-analysis [J].
Contopoulos-Ioannidis, DG ;
Giotis, ND ;
Baliatsa, DV ;
Ioannidis, JPA .
PEDIATRICS, 2004, 114 (01) :E111-E118
[26]   In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models [J].
Craig, W. A. ;
Andes, D. R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (10) :3492-3496
[27]  
Craig W A, 1990, Scand J Infect Dis Suppl, V74, P63
[28]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[29]   POSTANTIBIOTIC EFFECTS IN EXPERIMENTAL-INFECTION MODELS - RELATIONSHIP TO INVITRO PHENOMENA AND TO TREATMENT OF INFECTIONS IN MAN [J].
CRAIG, WA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 :149-158
[30]   Pharmacodynamics of doxycycline [J].
Cunha, BA ;
Domenico, P ;
Cunha, CB .
CLINICAL MICROBIOLOGY AND INFECTION, 2000, 6 (05) :270-273